Celera Corp.

Celera Corp. (CRA) is showing phenomenal growth over the next few years as shares continue to set higher highs.

Company Description

Celera Corp. is a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and optimize patient management.

The company also commercializes a wide range of molecular diagnostic products through its strategic alliance with Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases.

Modest Earnings...For Now

On Oct 28 Celera reported third-quarter results for calendar 2008 that included net revenues of $45.8 million, up from just $16.1 in the same quarter last year. All of the revenue growth was due to the acquisition of Berkeley HeartLab and Atria Genetics, which were bought nearly one year ago.

Earnings per share came to 1 cent per share, which met analyst expectations.

Explosive Growth Ahead

After teetering on the bring of profitability over the past few quarters, consensus estimates are relatively through the roof. The average estimate for the current fiscal year, which ends in June, is 11 cents, up from breaking even last year.

More impressively is the 37 cents per share projected for fiscal 2010, a 233% growth rate.

The Chart

Shares of CRA have broken through two levels of resistance it formed a nice trend. The stock continues to set higher highs and higher lows after it stabilized near $8 per share when setting its 52-week low. Take a look at the chart below.

Read the full analyst report on CRA